[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CO6270320A2 - Derivados de piperidina utiles como antagonistas del receptor orexina - Google Patents

Derivados de piperidina utiles como antagonistas del receptor orexina

Info

Publication number
CO6270320A2
CO6270320A2 CO09149373A CO09149373A CO6270320A2 CO 6270320 A2 CO6270320 A2 CO 6270320A2 CO 09149373 A CO09149373 A CO 09149373A CO 09149373 A CO09149373 A CO 09149373A CO 6270320 A2 CO6270320 A2 CO 6270320A2
Authority
CO
Colombia
Prior art keywords
alkyl
orexine
piperidine derivatives
halo
alkoxy
Prior art date
Application number
CO09149373A
Other languages
English (en)
Inventor
Alvaro Giuseppe
David Amantini
Sandro Belvedere
Yu Li
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0712887A external-priority patent/GB0712887D0/en
Priority claimed from GB0804317A external-priority patent/GB0804317D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CO6270320A2 publication Critical patent/CO6270320A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

1.- Un compuesto de formula (I):en la que Ar se selecciona entre el grupo que consiste en las formulas:donde R1 es alquilo (C1-4), halo, haloalquilo (C1-4), alcoxi (C1-4), haloalcoxi (C1-4), alquil (C1-4)-O-alquilo (C1-4), CN, NR5R6, donde R5 es H o alquilo (C1-4) y R6 es H o alquilo (C1-4); R2 es alquilo (C1-4), alquenilo (C1-4), HO-alquilo (C1-4), halo, haloalquilo (C1-4), alcoxi (C1-4), haloalcoxi (C1-4), alquil (C1-4)-O-alquilo (C1-4), CN, NR7R8, donde R7 es H o alquilo (C1-4) y R8 es H o alquilo (C1-4); R3 es alquilo (C1-4), halo, haloalquilo (C1-4), alcoxi (C1-4), haloalcoxi (C1-4), alquil (C1-4)-O-alquilo (C1-4), CN, NR9R10, donde R9 es H o alquilo (C1-4) y R10 es H o alquilo (C1-4); R3 es alquilo (C1-4), halo, haloalquilo (C1-4), alcoxi (C1-4), haloalcoxi (C1-4), alquil (C1-4)-O-alquilo (C1-4), CN, NR11R12, donde R11 es H o alquilo (C1-4) y R12 es H o alquilo (C1-4);n es 0 o 1;p es 0 o 1;q es 0 o 1;r es 0 o 1; o una sal farmacéuticamente aceptable del mismo.
CO09149373A 2007-07-03 2009-12-30 Derivados de piperidina utiles como antagonistas del receptor orexina CO6270320A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0712887A GB0712887D0 (en) 2007-07-03 2007-07-03 Novel compounds
GB0804317A GB0804317D0 (en) 2008-03-07 2008-03-07 Novel compounds

Publications (1)

Publication Number Publication Date
CO6270320A2 true CO6270320A2 (es) 2011-04-20

Family

ID=39789338

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09149373A CO6270320A2 (es) 2007-07-03 2009-12-30 Derivados de piperidina utiles como antagonistas del receptor orexina

Country Status (18)

Country Link
US (2) US20120095034A1 (es)
EP (1) EP2176258A1 (es)
JP (1) JP2010531848A (es)
KR (1) KR20100030635A (es)
CN (1) CN101796053A (es)
AR (1) AR067396A1 (es)
AU (1) AU2008270294A1 (es)
BR (1) BRPI0812981A2 (es)
CA (1) CA2691638A1 (es)
CL (1) CL2008001951A1 (es)
CO (1) CO6270320A2 (es)
DO (1) DOP2009000293A (es)
EA (1) EA201070091A1 (es)
IL (1) IL202665A0 (es)
MA (1) MA31470B1 (es)
PE (1) PE20090441A1 (es)
TW (1) TW200911242A (es)
WO (1) WO2009003993A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20100046047A (ko) * 2007-07-27 2010-05-04 액테리온 파마슈티칼 리미티드 2-아자-비시클로[3.3.0]옥탄 유도체
EP2207778A2 (en) * 2007-09-24 2010-07-21 Actelion Pharmaceuticals Ltd. Pyrrolidines and piperidines as orexin receptor antagonists
RU2010138640A (ru) * 2008-02-21 2012-03-27 Актелион Фармасьютиклз Лтд (Ch) Производные 2-аза-бицикло [2.2.1] гептана
CA2722347A1 (en) * 2008-04-30 2009-11-05 Actelion Pharmaceuticals Ltd Piperidine and pyrrolidine compounds
US8129384B2 (en) * 2008-10-09 2012-03-06 Glaxo Group Limited Imidazo[1,2-a]pyrazines as orexin receptor antagonists
US8093255B2 (en) 2008-10-09 2012-01-10 Glaxo Group Limited Imidazo[1,2-A]pyrimidines as orexin receptor antagonists
JP2012509911A (ja) * 2008-11-26 2012-04-26 グラクソ グループ リミテッド 新規の化合物
WO2010060472A1 (en) * 2008-11-26 2010-06-03 Glaxo Group Limited Imidazopyridazine derivatives acting as orexin antagonists
EP2358711A1 (en) * 2008-11-26 2011-08-24 Glaxo Group Limited Piperidine derivatives useful as orexin receptor antagonists
AU2009324238A1 (en) 2008-12-02 2010-06-10 Glaxo Group Limited N-{[(IR,4S,6R-3-(2-pyridinylcarbonyl)-3-azabicyclo [4.1.0] hept-4-yl] methyl}-2-heteroarylamine derivatives and uses thereof
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
US20120040991A1 (en) 2009-04-24 2012-02-16 Glaxo Group Limited 3-azabicyclo [4.1.0] heptanes used as orexin antagonists
USRE48841E1 (en) 2009-10-23 2021-12-07 Janssen Pharmaceutica Nv Disubstituted octahydropyrrolo[3,4-c]pyrroles as orexin receptor modulators
US8742106B2 (en) 2009-12-21 2014-06-03 Novartis Ag Disubstituted heteroaryl-fused pyridines
WO2011138266A1 (en) * 2010-05-03 2011-11-10 Evotec Ag Indolizine and imidazopyridine derivatives as orexin receptor antagonists
EP2638008B1 (en) * 2010-11-10 2015-07-01 Actelion Pharmaceuticals Ltd Lactam derivatives useful as orexin receptor antagonists
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
GB201101678D0 (en) 2011-02-01 2011-03-16 Rolls Royce Plc A cooling arrangement for a magnetic gearbox
NZ703448A (en) 2012-06-04 2017-07-28 Actelion Pharmaceuticals Ltd Benzimidazole-proline derivatives
TW201414727A (zh) 2012-10-10 2014-04-16 Actelion Pharmaceuticals Ltd 其係［鄰雙（雜）芳基］－［２－（間雙（雜）芳基）吡咯啶－１－基］甲酮衍生物之食慾素受體拮抗劑
KR20150130413A (ko) 2013-03-12 2015-11-23 액테리온 파마슈티칼 리미티드 오렉신 수용체 길항제로서의 아제티딘 아미드 유도체
GB201318222D0 (en) * 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
MA39163B1 (fr) 2013-12-03 2018-09-28 Idorsia Pharmaceuticals Ltd Forme cristalline de (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone et utilisation de celle-ci en tant qu'antagonistes des recepteurs de l'orexine
MA39165A1 (fr) 2013-12-04 2017-10-31 Actelion Pharmaceuticals Ltd Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires
TW201613864A (en) * 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US10370380B2 (en) 2015-11-23 2019-08-06 Sunshine Lake Pharma Co., Ltd. Octahydropyrrolo[3,4-c]pyrrole derivatives and uses thereof
KR102448342B1 (ko) 2016-03-10 2022-09-27 얀센 파마슈티카 엔.브이. 오렉신-2 수용체 길항제를 사용한 우울증의 치료 방법
US20190151304A1 (en) 2016-05-10 2019-05-23 Inserm (Institut National De La Santé Et De La Rechercjae Médicale Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
TW202400149A (zh) 2022-05-13 2024-01-01 瑞士商愛杜西亞製藥有限公司 經噻唑并芳基-甲基取代之環狀肼-n-甲醯胺衍生物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4399256B2 (ja) * 2001-06-28 2010-01-13 スミスクライン ビーチャム ピー エル シー オレキシン受容体アンタゴニストとしてのｎ−アロイル環状アミン誘導体

Also Published As

Publication number Publication date
WO2009003993A1 (en) 2009-01-08
DOP2009000293A (es) 2010-03-31
AU2008270294A1 (en) 2009-01-08
MA31470B1 (fr) 2010-06-01
US20090022670A1 (en) 2009-01-22
CL2008001951A1 (es) 2009-01-09
TW200911242A (en) 2009-03-16
EA201070091A1 (ru) 2010-06-30
JP2010531848A (ja) 2010-09-30
PE20090441A1 (es) 2009-05-08
US20120095034A1 (en) 2012-04-19
AR067396A1 (es) 2009-10-07
BRPI0812981A2 (pt) 2014-12-16
CN101796053A (zh) 2010-08-04
IL202665A0 (en) 2010-06-30
EP2176258A1 (en) 2010-04-21
CA2691638A1 (en) 2009-01-08
KR20100030635A (ko) 2010-03-18

Similar Documents

Publication Publication Date Title
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
AR056317A1 (es) Compuestos de oxindol y composicion farmaceutica
PE20140863A1 (es) Compuestos de benceno sustituidos con arilo o heteroarilo
CR11223A (es) Compuestos de biciclolactama sustituida
PE20141041A1 (es) Compuestos, metodos y formulaciones parasiticidas
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
AR061548A1 (es) 3-aminopirrolidino-4-lactamas sustituidas como inhibidoras de dipeptidilpeptidasa iv (dpp-iv), composiciones farmaceuticas que las comprenden y el uso de las mismas en el tratamiento de la diabetes ii.
PE20091381A1 (es) Inhibidores del virus de la hepatitis c
PE20071100A1 (es) Derivados de azepinoindol como agentes farmaceuticos
CR8744A (es) Compuestos terapeuticos
ECSP12006640A (es) Inhibidores heterocíclicos de aspartil proteasa
AR092490A2 (es) Indolil alquil amino derivados sustituidos como inhibidores de la histona desacetilasa
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
CO6231033A2 (es) Derivados y composiciones que comprenden isoindolina 4-0 sustituida y metodos para utilizar la misma
CO6170361A2 (es) Composiciones y metodos para modular receptores de c-kit y pdgfr
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
AR118123A2 (es) Derivados de isoxazolidina, proceso para preparar dichos compuestos, composición farmacéutica y combinación
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
CO5680412A2 (es) Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
CO5690551A2 (es) Derivados de tetrazol y metodos para el tratamiento con los mismos de trastornos relacionados con el metabolismo
MX2010006882A (es) Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica.
AR072726A1 (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
AR063805A1 (es) Derivados de triazol sustituidos como inhibidores de ksp. composiciones farmaceuticas.

Legal Events

Date Code Title Description
FC Application refused